We prioritize patient well-being by developing therapies that reduce toxicity and enhance survival rates. Our supportive care solutions aim to help patients manage treatment challenges effectively.

Our ongoing commitment to R&D focuses on innovative, next-generation oncology treatments. We continuously refine our offerings to ensure patients benefit from the latest advancements in cancer care.

We mainly serve healthcare providers, including hospitals, cancer treatment centers, and clinics, delivering our oncology and supportive care medicines directly to them.

Yes, we actively seek B2B partnerships for co-development, licensing, and distribution of our products globally, collaborating with other pharmaceutical and biotech firms.